Bioniz Therapeutics, a Californian biopharmaceutical company developing peptide therapeutics, has hired Fredrik Wiklund as Chief Operating Officer.
Over the last 20 years, Wiklund has amassed operational and executive experience in the biotechnology industry and has a proven track record in executing private and public financings, high-value partnering transactions, building commercial expertise in innovation-based companies and driving growth.
As a key member of the executive leadership team, Wiklund will be responsible for leading the company's business, operations, strategy, corporate development, finance, commercial planning, investor relations and corporate communications.
Wiklund joins Bioniz from Celladon where he was Vice President, Corporate Development and Investor Relations. He was also President and Chief Executive as the company merged with Eiger Biopharmaceuticals.
Prior to Celladon, Wiklund was Head of Corporate Development and Investor Relations at Tercica. Previously, Wiklund was an investment banker with Lehman Brothers where he assisted pharmaceutical and emerging biotechnology companies complete capital-raising and strategic transactions. He also has more than seven years of commercial experience, primarily with Gilead Sciences where he participated in the company's first product launch in 1996.